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Background: HIV-infected subjects with suboptimal CD4 restoration despite suppres-
sive combined antiretroviral treatment (cART) (immunodiscordant subjects) have been 
classically characterized after a variable period of time under cART. Recently, we have 
reported that an increased frequency of proliferating CD4 T-cells in these subjects is 
already present before the cART onset. The potential contribution of peripheral com-
pensatory homeostatic proliferation (HP) is yet unknown. We aimed to analyze the 
expression of HP-related cellular markers on CD4 T-cells of immunodiscordant subjects 
before cART.
Methods: We analyzed the expression of OX40 and α4β7 on peripheral CD4 T-cells from 
immunodiscordant and control subjects (n = 21 each group) before cART initiation, and 
also on available follow-up samples (after 24 month of suppressive cART). Additionally, 
we tested the expression of these markers in an in vitro system for the study of human 
HP processes.
results: Immunodiscordant subjects showed increased levels of OX40 and α4β7 on 
CD4 T-cells before cART initiation. While the cART tended to reduce these levels, immu-
nodiscordant subjects still maintained comparatively higher levels of OX40 and α4β7 
after 24 months under suppressive cART. These HP-related markers were upregulated 
in vitro during the human HP, especially during the fast HP.
conclusion: Our results are compatible with exacerbated HP processes in immunodis-
cordant subjects, already before the cART onset.
Keywords: immunodiscordant response to combined antiretroviral treatment, low cD4 recovery, homeostatic 
parameters, homeostatic proliferation, OX40, α4β7, cD4 T-cell homeostasis, hiV
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inTrODUcTiOn
Those subjects starting combined antiretroviral treatment (cART) 
with low CD4 counts and maintaining such low levels despite 
persistent suppression of viremia (immunodiscordant subjects 
with low-level CD4) constitute a particularly relevant popula-
tion among HIV-infected subjects. They show increased rates of 
clinical complications than those subjects having a subsequent 
proper CD4-cell recovery (1, 2). Unfortunately, the mechanisms 
triggering such response still remain unknown.
These immunodiscordant subjects have been exhaustively 
studied after cART onset, when immunodiscordant response 
to cART has already taken place (3, 4), but less is known about 
immune alterations preexisting before cART initiation and, there-
fore, preceding such anomalous response to the treatment. Our 
group has been a pioneer in reporting immune alterations pre-
ceding the low CD4 recovery in this scenario (5, 6). Interestingly, 
these immunodiscordant subjects showed increased frequencies 
of proliferating CD4 T-cells already before cART initiation (5), 
denoting an early impairment of CD4 T-cell homeostasis, which 
deserves further research.
Globally, in T-cell lymphopenia conditions, a peripheral com-
pensatory homeostatic proliferation (HP) of preexisting T-cells 
occurs (7). Two different types of HP have been extensively 
described: a commensal/self-antigen-driven fast HP and a 
cytokine-driven slow HP (mainly IL7 and IL15) (8), although 
both types of stimuli can synergize impacting each type of HP 
(9, 10). Recent works have found that fast HP specifically upregu-
lates the tumor necrosis factor receptor superfamily member 4 
(OX40) (11, 12), and that the blockade of OX40–OX40L interac-
tion hamper the fast HP, taking place mainly in mesenteric lymph 
nodes (11). In this sense, a gut-homing imprinting (α4β7-integrins) 
has also been associated with the fast HP (11), but also with the 
slow HP in HIV-infected subjects after IL7 administration (13).
Our aim was to analyze the expression of OX40 and α4β7 on 
CD4 T-cells of immunodiscordant subjects before the cART onset. 
Additionally, in an in vitro model for the study the human HP we 
explored the modulation of these markers during such processes.
MaTerials anD MeThODs
subjects and samples
Samples were selected from the Spanish AIDS Research Network 
Cohort (CoRIS) (14) and kindly provided by its HIV BioBank 
(15). Samples were processed following current procedures and 
frozen immediately after their reception. All patients participat-
ing in the study gave their informed consent and institutional 
ethical committees approved protocols. We selected pre-cART 
samples (up to 6 months before cART onset) of peripheral blood 
mononuclear cells from antiretroviral-naïve subjects who had 
started cART with <200 CD4/mm3 and did not reach 250 CD4/
mm3 after 24 months of suppressive treatment (Low CD4 recov-
ery subjects; LR-subjects), and subjects who also started cART 
with <200 CD4/mm3 but achieved more than 250 CD4/mm3 
after 24-months of suppressive treatment (High CD4 recovery 
subjects, HR-subjects). Both groups of subjects were matched by 
sex, age, viral load, and baseline CD4 counts. Finally, 21 subjects 
per group were included (a flow chart of subject’s selection is 
shown in Figure S1 in Supplementary Material). Depending 
on sample availability, additional post-cART follow-up samples 
(24 ± 6 months on cART) were also analyzed.
For the in vitro T-cell culture experiments, buffy coats from 
HIV-1 and Hepatitis C Virus (HCV) seronegative anonymous 
donors from the Centro Regional de Transfusión Sanguínea de 
Sevilla-Huelva y Banco de Tejidos (Seville, Spain) were obtained. 
The study was approved by the local Ethical Committee and was 
performed according to the European Union guidelines and the 
Declaration of Helsinki.
immunophenotyping
After thawing, cells were stained with surface antibodies (detailed 
in Supplemental Methods in Supplementary Material). Viable 
cells were identified using LIVE/DEAD fixable Aqua Blue 
Dead Cell Stain (Life Technologies, USA). The homing-related 
molecules α4-integrin and β7-integrin, and the TNFR-related 
molecule OX40 (CD134) were analyzed. A schematic diagram of 
the gating strategy used is shown in Figure S2 in Supplementary 
Material. Flow cytometry was performed on a LSR Fortessa (BD, 
USA). The analysis was performed using FlowJo version 9.2 (Tree 
Star) and data are expressed as frequencies (%).
In Vitro culture of human lymphocytes
The in vitro culture used for the study of HP was performed as 
previously described (10). Briefly, untouched CFSE-dyed naïve 
CD4 T-cells were seeded in supplemented medium (RPMI 1640 
supplemented with 10% fetal bovine serum, 1.7 mM glutamine, 
100  µl/ml streptomicine and 100  U/ml peniciline), and stimu-
lated with irradiated autologous aAPCs (1/1 ratio aAPCs/Naïve) 
and rIL7 (10 ng/ml). Finally, after 10 days of culture, cells were 
collected and immunophenotyped.
statistical analyses
Variables from in vivo analyses were expressed as median values 
and interquartile range. Mann–Whitney U and Wilcoxon rank 
test were used to analyze unpaired and paired comparisons, 
respectively. For analyses of cellular markers in the culture, 
the variables were expressed as mean and SD. A p-value < 0.05 
was considered statistically significant. Statistical analysis was 
performed using the Statistical Package for the Social Sciences 
software (SPSS 22.0, USA). Graphs were created using Prism 
version 5.0 (GraphPad Software, USA).
resUlTs
higher levels of OX40 and α4β7 on  
cD4 T-cells of lr-subjects Before  
and after carT instauration
The baseline clinical characteristics of LR- and HR-subjects are 
described elsewhere (5). Most importantly, groups did not differ 
statistically in matched variables, nor did in other clinical vari-
ables as time from HIV diagnosis or route of transmission. Before 
cART initiation, LR-subjects showed higher frequencies of OX40+ 
CD4+ T-cells (Figure 1A), and a trend to higher frequencies of 
FigUre 1 | Expression of OX40 and α4β7 in CD4 T-cells of LR-subjects at combined antiretroviral treatment onset. (a) Frequency of OX40+CD4+ T-cells;  
(B) Frequency of α4hiβ7hi CD4+ T-cells. After excluding outlier value (*) statistical significance was p = 0.009. Data were determined using multiparametric flow 
cytometry and are expressed as median value and interquartile range (IQR). Mann–Whitney test was used for the statistical significance calculation.
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α4+β7+ CD4+ T-cells (LR = 9.2 [5.2–12.1]; HR = 5.0 [2.5–9.0]; 
p = 0.051), that reached statistical significance when comparing 
frequencies of α4hiβ7hi CD4+ T-cells (Figure 1B).
According to the classification criteria, after 24 months under 
cART, LR-, and HR-subjects had achieved 208 [141–234] and 429 
[372–524] CD4 T-cells/mm3, respectively. Additionally, we longitu-
dinally compared samples of 10 LR and 8 HR-subjects. Suppressive 
cART tended to reduce levels of OX40 (p = 0.069 and p = 0.036 
for longitudinal comparisons of LR- and HR-subjects, respectively) 
and α4hiβ7hi (p = 0.093 and p = 0.116 for longitudinal comparisons 
of LR- and HR-subjects, respectively). However, LR-subjects still 
sustained higher levels than HR-subjects for both markers, OX40 
(LR = 10.0 [11.3–7.1]; HR = 5.8 [7.4–5.0]; p = 0.034) and α4hiβ7hi 
(LR = 4.9 [6.4–2.7]; HR = 1.5 [3.7–1.0]; p = 0.025).
OX40 and α4β7-integrins are Upregulated 
During hP of human cD4 T-cells
We explored the modulation of these HP-related markers previ-
ously associated with the HP using an in vitro cell culture specifi-
cally designed to study such processes in human T-lymphocytes 
(10). This culture system allowed us analyzing the expression of 
such markers as a consequence of each type of HP, the slow and 
the fast HP. Dilution of CFSE was used for identification of differ-
ent types of HP (Figure 2A). Especifically, fast HP was defined as 
viable CD4 T-cells which fully diluted CFSE (and acquired mem-
ory phenotype), while slow HP was defined as viable CD4 T-cells 
which partially diluted CFSE (but maintained naïve phenotype) 
(10). We observed that OX40, α4-integrin, and β7-integrin were 
upregulated on human lymphocytes during the HP induced by 
homeostatic stimuli (Figure 2B). OX40 was mainly expressed in 
cells undergoing fast HP (Figure 2C). Similarly, when consider-
ing the coexpression of α4 and β7 as a single marker, a greater 
specificity in discriminating fast and slow HP was observed for 
α4highβ7high compared with α4+β7+ (Figures 2D,E). As it can be 
observed, the percentages of OX40+ and α4highβ7high cells were 
around the 50 and 30%, respectively, among those generated 
during the fast HP, whereas this percentage was lower than 10 
and 2%, respectively, among those generated by slow HP.
DiscUssiOn
We report here that HIV-infected subjects with low CD4 T-cell 
counts and immunodiscordant response to cART present higher 
expression of OX40 and α4β7 on CD4 T-cells before and after 
suppressive cART than their control group. These markers, which 
have been related to HP mainly in animal models, were also 
upregulated during HP of human T-lymphocytes, mostly during 
fast HP, similarly as it occurs in vivo.
While a higher expression of markers of activation, senescence, 
exhaustion, and proliferation on CD4 T-cells has been extensively 
reported in immunodiscordant subjects after cART (16–19), they 
only differed in a higher expression of Ki67 on CD4 T-cells when 
all these markers were compared before the cART onset (5). 
Interestingly, in this comparative study, microbial translocation, 
HCV coinfection, baseline viral load, or viral tropism did not dif-
fer either between groups (5). Since HP is an additional potential 
cause of a higher proliferative status, especially in lymphopenia 
scenarios (7) such as HIV-infection (20), we aimed here to explore 
the expression of HP-related markers in this particular context.
It is well-known that immunodiscordant subjects present 
higher frequencies of Treg (21, 22) and Th17 (23, 24) after 
cART initiation. Additionally, we have recently reported that 
increased frequencies of both Treg and Th17 are already present 
before cART initiation (5, 6) in these subjects. Interestingly, the 
fast HP is able to generate Treg (10, 25) and Th17 (11), and the 
costimulatory molecule OX40 is a key mediator in such process 
(11, 12). Moreover, we report here that OX40 is also upregulated 
specifically during the human fast HP. Thus, the higher frequency 
of OX40  +  CD4 T-cells found now in immunodiscordants, 
together with the previous data, point to an exacerbation of the 
fast HP process in this scenario. Importantly, the OX40–OX40L 
axis has been associated with the production of proinflammatory 
cytokines such as IL6 by dendritic cells (26) and with inflammatory 
disorders (27), suggesting that HP, through OX40 upregulation, 
could also contribute to the higher inflammation observed in 
this scenario (5). Also of relevance, inflammatory cytokines such 
as IL6 have been reported to increase proliferation of memory 
CD4 T-cells but also lead to downregulation of CD127 (IL7 
FigUre 2 | OX40 and α4β7 expression during the homeostatic proliferation (HP) process of human naïve CD4 T-cells. Untouched CFSE-stained naïve CD4 T-cells 
were culture in presence of rIL7 (10 ng/ml) and with irradiated autologous APCs (1/1 ratio): (a) representative CFSE histograms used for identification of different 
types of HP at baseline (0 day) and after 10 days of culture, (B) OX40, α4-integrin, and β7-integrin upregulation during HP, (c) frequencies of OX40 in the different 
types of HP subsets, (D) frequencies of α4+β7+ in the different types of HP subsets, (e) frequencies of α4highβ7high in the different types of HP subsets. Frequencies  
of both OX40 and α4β7 were calculated after background substation from baseline condition. Data are expressed as mean value and SD.
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receptor-α) (28). Therefore, inflammatory cytokines induced by 
the OX40–OX40L interaction could theoretically exacerbate fast 
HP and likewise hamper slow HP. However, further studies are 
necessary to a better understanding of the specific relationship 
between inflammatory cytokines and HP.
The T-cell trafficking from blood to the gut-associated lym-
phoid tissue (GALT) is mediated by the β7- and α4-integrins 
among other homing-molecules (29, 30). Here, we have found 
a higher frequency of α4highβ7high CD4 T-cells in immunodis-
cordant subjects before and after suppressive cART. Using an 
in vitro system, we previously reported that both, fast and slow 
human HP upregulate β7-integrin (10). Additionally, we have 
now observed that human HP also upregulates α4-integrin and 
that α4+β7+ CD4 T-cells, but especially α4highβ7high CD4 T-cells, 
are mainly generated during fast HP. Also relevant, immuno-
discordant subjects before cART initiation did not show higher 
levels of peripheral IL7 (5), the main cytokine driving slow HP. 
Altogether is consistent with the fast HP as the more plausible HP 
mechanism leading to the increased expression of α4β7 on CD4 
T-cells in this particular context. Interestingly, α4β7-integrins 
favor the HIV colonization of GALT and the establishment of 
mucosal HIV reservoir (31). In this line, the higher expression 
of α4β7 in CD4 T-cells recently reported in a different cohort 
of immunodiscordant subjects under suppressive cART, was 
correlated with a higher proviral HIV load (24). Additionally, 
the expression of OX40 on CD4 T-cells has been associated with 
a high metabolic activity which is ultimately associated with a 
higher permissibility to HIV infection (32), and HP process itself 
has been also associated with higher amounts of HIV provirus 
(33). Therefore, all these data suggest that the higher HP before of 
cART onset in immunodiscordant subjects could imply a higher 
proviral HIV load, but additional studies are necessary to clarify 
this topic.
Our cohort study has a limited number of subjects, but it 
is counterbalanced by a clean case:control design allowing the 
adjustment by the main associated risk factors to the immu-
nodiscordant response to cART. On the other hand, an in vivo 
human model for the study of HP, including anatomical support, 
would have been preferable but is not easily affordable. However, 
the in vitro model was useful to corroborate the upregulation of 
studied markers during human HP.
In summary, we have found that immunodiscordant subjects 
with low-level CD4 show an early and specific increase in the 
expression of OX40 and α4β7 on CD4 T-cells. The longitudinal 
exploration allowed proving that such alteration persists after 
suppressive cART, despite some extent of improvement. These 
novel features and our previous related data are all consistent with 
a promptly enhanced HP in this scenario.
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